Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Beliefs about hydroxyurea in youth with sickle cell disease
source: Hematology/oncology and stem cell therapy
year: 2018
authors: Badawy SM, Thompson AA, Liem RI
summary/abstract:Background:
Hydroxyurea reduces complications and improves health-related quality of life (HRQOL) in sickle cell disease (SCD) patients, however adherence remains suboptimal. Understanding patients’ views of hydroxyurea is critical to optimize adherence, particularly in adolescents and young adults (AYA). Study objectives were to assess beliefs about hydroxyurea using the Beliefs about Medicines Questionnaire (BMQ), and to examine the relationship of patients’ beliefs to their hydroxyurea adherence and HRQOL.
Methods:
Thirty-four AYA with SCD participated in a cross-sectional study January-December 2015. Study assessments included BMQ to examine beliefs about hydroxyurea; Visual Analogue Scale (VAS) to assess hydroxyurea adherence; and Patient Reported Outcomes Measurement Information System (PROMIS®) to evaluate HRQOL.
Results:
Participants (41% female, 91% Black) had median age of 13.5 (IQR 12-18) years. Participants’ concerns about overuse of medications correlated with concerns about hydroxyurea (rs = 0.36, p = 0.04) and overall harm of medications (rs = 0.5, p = 0.003). Participants’ age positively correlated with the necessity of hydroxyurea (rs = 0.45, p = 0.007). Participants’ concerns about hydroxyurea and overuse of medications positively correlated with anxiety (rs = 0.41, p = 0.02; rs = 0.44, p = 0.01) and depression (rs = 0.37, p = 0.04; rs = 0.54, p = 0.001), but inversely correlated with peer relationships (rs = -0.45, p = 0.03; rs = -0.44, p = 0.03), respectively, suggesting better HRQOL with concerns. Fifty percent of participants reported low hydroxyurea adherence (VAS < 80%), which was more seen in patients with higher concerns about hydroxyurea (p = 0.02).
Conclusions:
Beliefs about hydroxyurea correlated with HRQOL scores and adherence levels. Addressing patients’ concern about hydroxyurea and medications overall as well as routine assessment of adherence and beliefs could help to overcome adherence barriers.
DOI: 10.1016/j.hemonc.2018.01.001
read more full text
Related Content
-
Prevalence and Correlates of Growth Failure in Young African Patients With Sickle Cell DiseaseGrowth failure (GF) in children with sic...
-
Sickle Cell Disease, Hydroxyurea: What You Should Knowhttps://www.onescdvoice.com/wp-content/u...
-
Shared Decision Making for Hydroxyurea Treatment Initiation in Children With Sickle Cell AnemiaClinical trials have demonstrated hydrox...
-
Amy E. Sobota, MD, MPHAmy E. Sobota is a pediatric hematologis...
-
Adulting is especially difficult for youth with special health care needsThere are approximately 4.3 million adol...
-
4 Transition Stages of Sickle Cell Disease and Tips for Each Stagehttps://www.onescdvoice.com/wp-content/u...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.